Immunotoxins Market - Forecast(2021 - 2026)

Report Code: HCR 0239 Report Format: PDF + Excel (Delivery in 48 Hrs)

Immunotoxin Market Overview

Immunotoxin Market size was valued at $46.8 Million in 2020, growing at a CAGR of 7.8% during the forecast period 2021-2026. Immunotoxins are new generation of chemotherapeutic agents that are innovated to contain the particularity of cytotoxicity that are extracted from plants or bacteria source which helps to terminate cancer cells. It is protein that contain an antigen along with an antibody or growth factor that binds directly to the target. A particular cell-targeting constituent, normally a monoclonal antibody (mAb) linked to a cell-killing toxin, consists of an immunotoxin. Immunotoxins are formed by chemical conjugation of the antibody to the entire protein toxin, lacking its natural binding domain. Bacterial toxins are most commonly used in immunotoxins which include Diphtheria toxin (DT) and the toxin from Pseudomonas exotoxin (PE). Toxins used in immunotoxin systems are derived from fungi, bacteria and plants, although most work by inhibiting protein synthesis. The Pseudomonas exotoxin (PE) toxin and Diphtheria toxin maybe are bacterial toxins widely used in immunotoxins (DT). Increasing development of advance and efficient technology along with increasing incidence of cancer are some factors driving the growth of the market. 

Report Coverage

The report: “Immunotoxin Market – Forecast (2021-2026)”, by IndustryARC covers an in-depth analysis of the following segments of the Immunotoxin Market. 
By Toxins Type: Pseudomonas Exotoxin (PE), Diphtheria Toxin (DT), Anthrax Based Toxins, Ribosomes Inactivating Protein Based Immunotoxins, Ribonucleases Based Immunotoxins and Others.
By Application: Solid Tumors, Leukemias and Others.
By End User: Hospitals and Clinics, Cancer and Radiation Therapy Centers, Research Labs and Others.
By Geography: North America (U.S, Canada, Mexico), Europe (Germany, UK, France, Italy, Spain and Others), Asia-Pacific (China, Japan India, Australia & New Zealand, South Korea and Others) and RoW (Middle East, South America and Africa).

Key Takeaways

  • The growing incidence of cancer, increasing R&D funding and venture capital investment and development factors are accelerating the Immunotoxin demand over the forecast period.
  • Increasing research of immunotoxins in bone marrow transplantation and rising new developments in monoclonal antibody technology as well as in the molecular design of toxins have created new clinical application in organ transplantation and bone marrow transplantation is likely to improve the adoption of Immunotoxins.
  • Geographically, North America Immunotoxin Market held the largest revenue share of 41% in 2020 owing rising public & private funding for R&D in this region.
  • Detailed analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market is provided in the Immunotoxin Market

Immunotoxin Market Segment Analysis - By Application:

In 2020, Leukemia segment dominated the Immunotoxin Market in terms of revenue and is estimated to grow at a CAGR of 7.3%. Leukemia is a blood cancer caused by a rise in the number of white blood cells in the body and many types exists such as acute lymphoblastic leukemia, acute myeloid leukemia and chronic lymphocytic leukemia. LMB-2 is a recombinant immunotoxin which is prepared by using recombinant DNA technology used for treating chronic lymphocytic leukemia (CLL). In 2018, US Food and Drug Administration (FDA) have approved AstraZeneca’s Lumoxiti, an Immunotoxin-based drug for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (HCL). The approval of such drugs made from immunotoxins, is set to drive the demand of immunotoxins in this application. Solid Tumor is estimated to record the fastest growth rate during the forecast period 2021-2026. 

Immunotoxin Market Segment Analysis - By End User:

In 2020, Research Labs segment dominated the Immunotoxin Market in terms of revenue and is estimated to grow at a CAGR of 8.1% owing towards the growing government support for research lab this leads to rising number of research labs which is driving the growth of this segment. Rising technological advancement in research lab including Integration of AI and machine learning tools in drug discovery & development is also increasing growth of this segment. Rising growth of pharmaceutical companies in terms of research, development, production, and distribution of medications is driving the growth of this market. Pharmaceuticals companies and biotechnology companies are focused on research and development of immunotoxins drugs for cancer treatment. Cancer and Radiation Therapy Centers is estimated to record the fastest growth rate during the forecast period 2021-2026 owing to increasing prevalence of cancer across the globe thus leading to the rising the number of patients going for cancer therapies in cancer and radiation therapy centers, which in turn drive the segment growth.

Immunotoxin Market Segment Analysis - By Geography:

In 2020, the North America dominated Immunotoxin Market in terms of revenue with a market share of 41% owing towards rising public & private funding for R&D in this region with increased usage of immunotoxins to treat patients with refractory hairy cell leukemia which is an uncommon hematological malignancy characterized by an accumulation of abnormal B lymphocytes is increasing the growth of the Immunotoxins Market. The Public Health Agency of Canada, in collaboration with other governmental and non-governmental organizations, conducts national surveillance of cancer to support the planning and evaluation of cancer-related policies, programs, and services. The prevalence of cancer increases with age. By 70 years of age, more than 20% of Canadians get diagnosed with cancer during their lifetime, increasing the need of immunotoxins, stimulating the growth of the Immunotoxins market. Cancer is increasing among adolescents and young adults in U.S. owing to the fact that they are less financially stable than older adults and also have lower rates of health insurance coverage which in turn is increasing the growth of the immunotoxins market in this region. Asia-Pacific is forecast to record the fastest growth rate during the forecast period 2021-2026 owing to the rapidly increasing cancer burden of colorectal, prostate, female breast cancers in addition to a high occurrence of infection-related and digestive cancers. According to the World Health Organization’s International Agency for Research on Cancer, nearly one in two men in New Zealand and Australia have a risk of getting some form of cancer in their lifetime which is in turn increasing the demand of immunotoxins, thereby driving the growth in the region.

Immunotoxin Market: Market Share (%) by Region, 2020
 

Immunotoxin Market Drivers

Rising Development on Advance and Efficient Technology

Technological advancement of immunotoxins is increasing rapidly and can be divided into three generations. The improvements and developments in first- and second-generation increase the preparation of new immunotoxin that constructs with anti-tumor activity and is driving the growth of this market. The first generation was generated by glycosylated toxin with a mAb or a ligand through a cross-linking reagent that forms disulfide bonds between toxin and mAb or ligand. DAB389IL2 was the first immunotoxin-based drug approved by the Food and Drug Administration that use against cancer cells. Recent research published on Immunotoxin Screening System in 2020, focuses on modifying the screening strategies with single B cell antibody technologies, allowing improved potential of antibodies and thus for immunotoxins.

Immunotoxin Market Challenges

Increased Side Effects of Immunotoxins

Increasing side effects such as diarrhea, nausea or mild fever in the field of cancer therapy, but even some side effects are extreme and dose-limiting limits the growth of the market. The immunogenicity of immunotoxin and its toxicity are challenging the market growth. For instance, Ricin-based immunotoxins can cause a capillary leak syndrome and Pseudomonas exotoxin A are reported to damage the liver. Other side effects such as hepatotoxicity, which brought about the termination of some clinical trials also restraining the growth of this market.

Immunotoxin Market Landscape:

Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players the Immunotoxin Industry. Immunotoxin key companies include Thermo Fisher Scientific, Merck KGaA, Creative Biolabs, The Native Antigen Company, List Biological Laboratories Inc., Cayman Chemical Company, Meridian Bioscience Inc., LifeSpan BioSciences, Inc., and Antibody Research Corporation.

Acquisitions/Product Launches:

  • In December 2020, Thermo Fisher Scientific expanded its clinical supply chain services in Europe. The company has expanded its pharma services in two new state-of-the-art facilities in Rheinfelden and Weil am Rhein, Germany. These facilities combined with established regulatory expertise will give customers the continuity and in-region capabilities to support clinical trials across multiple therapy areas.
  • In April 2019, Meridian Bioscience, Inc. acquired the business of GenePOC Inc., a Quebec City, Quebec, Canada based provider of molecular diagnostic instruments and assays. This acquisition helped meridian’s portfolio of molecular diagnostics portfolio.

Related Reports:

Report Code: HCR 0038
Report Code: HCR 0051

For more Lifesciences and Healthcare Market reports, please click here
1. Immunotoxin Market - Overview
    1.1 Definitions and Scope
2. Immunotoxin Market - Executive Summary
    2.1 Market Revenue, Market Size and Key Trends
    2.2 Key trend by Toxin Types
    2.3 Key trends by Application
    2.4 Key trends by End User
    2.5 Key trends by Geography
3. Immunotoxin Market - Comparative Analysis
    3.1 Product Benchmarking – Key Companies
    3.2 Financial Analysis– Key Companies
    3.3 Market Share Analysis
    3.4 Patent Analysis
    3.5 Pricing Analysis- Average Selling Price
4. Immunotoxin Market - Startup Companies Scenario Premium
    4.1 Key Startup Company Analysis by
    4.1.1 Investment
    4.1.2 Revenue
    4.1.3 Venture Capital and Funding Scenario
5. Immunotoxin Market - Forces
    5.1 Market Drivers
    5.2 Market Constraints/Challenges
    5.3 Porters Five Force Model
        5.3.1 Bargaining power of suppliers
        5.3.2 Bargaining powers of customers
        5.3.3 Threat of new entrants
        5.3.4 Rivalry among existing players
        5.3.5 Threat of substitutes 
6. Immunotoxin Market – Strategic Analysis
    6.1 Value Chain Analysis
    6.2 Opportunities Analysis
    6.3 Market Life Cycle
7. Immunotoxin Market – By Toxin Type (Market Size –$Million/$Billion)
    7.1 Pseudomonas Exotoxin (PE)
    7.2 Diphtheria Toxin (DT)
    7.3 Anthrax Based Toxins
    7.4 Ribosomes Inactivating Protein Based Immunotoxins
    7.5 Ribonucleases based Immunotoxins
    7.6 Others
8. Immunotoxin Market – By Application (Market Size –$Million/$Billion)
    8.1 Solid Tumors
    8.2 Leukemias
    8.3 Others
9. Immunotoxin Market – By End User (Market Size –$Million/$Billion)
    9.1 Hospitals and Clinics
    9.2 Cancer and Radiation Therapy Centers
    9.3 Research Labs
    9.4 Others
10. Immunotoxin Market - By Geography (Market Size –$Million/$Billion)
    10.1 North America
        10.1.1 U.S.
        10.1.2 Canada
        10.1.3 Mexico
    10.2 Europe
        10.2.1 U.K.
        10.2.2 Germany
        10.2.3 France
        10.2.4 Italy
        10.2.5 Spain
        10.2.6 Russia
        10.2.7 Rest of Europe
    10.3 Asia-Pacific
        10.3.1 China
        10.3.2 India
        10.3.3 Japan
        10.3.4 South Korea
        10.3.5 Australia & New Zealand
        10.3.6 Rest of Asia-Pacific
    10.4 South America
        10.4.1 Brazil
        10.4.2 Argentina
        10.4.3 Rest of South America
    10.5 Rest of the World
        10.5.1 Middle East
        10.5.2 Africa
11. Immunotoxin Market - Entropy
12. Immunotoxin Market Company Analysis
    12.1 Company 1
    12.2 Company 2
    12.3 Company 3
    12.4 Company 4
    12.5 Company 5
    12.6 Company 6
    12.7 Company 7
    12.8 Company 8
    12.9 Company 9
    12.10 Company 10
"*Financials for private companies would be provided on a best efforts basis”.
List of Tables
Table 1 Immunotoxins Market Overview 2019-2024
Table 2 Immunotoxins Market Leader Analysis 2018-2019 (US$)
Table 3 Immunotoxins MarketProduct Analysis 2018-2019 (US$)
Table 4 Immunotoxins MarketEnd User Analysis 2018-2019 (US$)
Table 5 Immunotoxins MarketPatent Analysis 2013-2018* (US$)
Table 6 Immunotoxins MarketFinancial Analysis 2018-2019 (US$)
Table 7 Immunotoxins Market Driver Analysis 2018-2019 (US$)
Table 8 Immunotoxins MarketChallenges Analysis 2018-2019 (US$)
Table 9 Immunotoxins MarketConstraint Analysis 2018-2019 (US$)
Table 10 Immunotoxins Market Supplier Bargaining Power Analysis 2018-2019 (US$)
Table 11 Immunotoxins Market Buyer Bargaining Power Analysis 2018-2019 (US$)
Table 12 Immunotoxins Market Threat of Substitutes Analysis 2018-2019 (US$)
Table 13 Immunotoxins Market Threat of New Entrants Analysis 2018-2019 (US$)
Table 14 Immunotoxins Market Degree of Competition Analysis 2018-2019 (US$)
Table 15 Immunotoxins MarketValue Chain Analysis 2018-2019 (US$)
Table 16 Immunotoxins MarketPricing Analysis 2019-2024 (US$)
Table 17 Immunotoxins MarketOpportunities Analysis 2019-2024 (US$)
Table 18 Immunotoxins MarketProduct Life Cycle Analysis 2019-2024 (US$)
Table 19 Immunotoxins MarketSupplier Analysis 2018-2019 (US$)
Table 20 Immunotoxins MarketDistributor Analysis 2018-2019 (US$)
Table 21 Immunotoxins Market Trend Analysis 2018-2019 (US$)
Table 22 Immunotoxins Market Size 2018 (US$)
Table 23 Immunotoxins Market Forecast Analysis 2019-2024 (US$)
Table 24 Immunotoxins Market Sales Forecast Analysis 2019-2024 (Units)
Table 25 Immunotoxins Market, Revenue & Volume,By End-User , 2019-2024 ($)
Table 26 Immunotoxins MarketBy End-User , Revenue & Volume,By Healthcare, 2019-2024 ($)
Table 27 Immunotoxins MarketBy End-User , Revenue & Volume,By Research Labs , 2019-2024 ($)
Table 28 North America Immunotoxins Market, Revenue & Volume,By End-User , 2019-2024 ($)
Table 29 South america Immunotoxins Market, Revenue & Volume,By End-User , 2019-2024 ($)
Table 30 Europe Immunotoxins Market, Revenue & Volume,By End-User , 2019-2024 ($)
Table 31 APAC Immunotoxins Market, Revenue & Volume,By End-User , 2019-2024 ($)
Table 32 Middle East & Africa Immunotoxins Market, Revenue & Volume,By End-User , 2019-2024 ($)
Table 33 Russia Immunotoxins Market, Revenue & Volume,By End-User , 2019-2024 ($)
Table 34 Israel Immunotoxins Market, Revenue & Volume,By End-User , 2019-2024 ($)
Table 35 Top Companies 2018 (US$)Immunotoxins Market, Revenue & Volume,,
Table 36 Product Launch 2018-2019Immunotoxins Market, Revenue & Volume,,
Table 37 Mergers & Acquistions 2018-2019Immunotoxins Market, Revenue & Volume,,

List of Figures
Figure 1 Overview of Immunotoxins Market 2019-2024
Figure 2 Market Share Analysis for Immunotoxins Market 2018 (US$)
Figure 3 Product Comparison in Immunotoxins Market 2018-2019 (US$)
Figure 4 End User Profile for Immunotoxins Market 2018-2019 (US$)
Figure 5 Patent Application and Grant in Immunotoxins Market 2013-2018* (US$)
Figure 6 Top 5 Companies Financial Analysis in Immunotoxins Market 2018-2019 (US$)
Figure 7 Market Entry Strategy in Immunotoxins Market 2018-2019
Figure 8 Ecosystem Analysis in Immunotoxins Market2018
Figure 9 Average Selling Price in Immunotoxins Market 2019-2024
Figure 10 Top Opportunites in Immunotoxins Market 2018-2019
Figure 11 Market Life Cycle Analysis in Immunotoxins Market
Figure 12 GlobalBy End-User Immunotoxins Market Revenue, 2019-2024 ($)
Figure 13 Global Immunotoxins Market - By Geography
Figure 14 Global Immunotoxins Market Value & Volume, By Geography, 2019-2024 ($) 
Figure 15 Global Immunotoxins Market CAGR, By Geography, 2019-2024 (%)
Figure 16 North America Immunotoxins Market Value & Volume, 2019-2024 ($)
Figure 17 US Immunotoxins Market Value & Volume, 2019-2024 ($)
Figure 18 US GDP and Population, 2018-2019 ($)
Figure 19 US GDP – Composition of 2018, By Sector of Origin
Figure 20 US Export and Import Value & Volume, 2018-2019 ($)
Figure 21 Canada Immunotoxins Market Value & Volume, 2019-2024 ($)
Figure 22 Canada GDP and Population, 2018-2019 ($)
Figure 23 Canada GDP – Composition of 2018, By Sector of Origin
Figure 24 Canada Export and Import Value & Volume, 2018-2019 ($)
Figure 25 Mexico Immunotoxins Market Value & Volume, 2019-2024 ($)
Figure 26 Mexico GDP and Population, 2018-2019 ($)
Figure 27 Mexico GDP – Composition of 2018, By Sector of Origin
Figure 28 Mexico Export and Import Value & Volume, 2018-2019 ($)
Figure 29 South America Immunotoxins MarketSouth America 3D Printing Market Value & Volume, 2019-2024 ($)
Figure 30 Brazil Immunotoxins Market Value & Volume, 2019-2024 ($)
Figure 31 Brazil GDP and Population, 2018-2019 ($)
Figure 32 Brazil GDP – Composition of 2018, By Sector of Origin
Figure 33 Brazil Export and Import Value & Volume, 2018-2019 ($)
Figure 34 Venezuela Immunotoxins Market Value & Volume, 2019-2024 ($)
Figure 35 Venezuela GDP and Population, 2018-2019 ($)
Figure 36 Venezuela GDP – Composition of 2018, By Sector of Origin
Figure 37 Venezuela Export and Import Value & Volume, 2018-2019 ($)
Figure 38 Argentina Immunotoxins Market Value & Volume, 2019-2024 ($)
Figure 39 Argentina GDP and Population, 2018-2019 ($)
Figure 40 Argentina GDP – Composition of 2018, By Sector of Origin
Figure 41 Argentina Export and Import Value & Volume, 2018-2019 ($)
Figure 42 Ecuador Immunotoxins Market Value & Volume, 2019-2024 ($)
Figure 43 Ecuador GDP and Population, 2018-2019 ($)
Figure 44 Ecuador GDP – Composition of 2018, By Sector of Origin
Figure 45 Ecuador Export and Import Value & Volume, 2018-2019 ($)
Figure 46 Peru Immunotoxins Market Value & Volume, 2019-2024 ($)
Figure 47 Peru GDP and Population, 2018-2019 ($)
Figure 48 Peru GDP – Composition of 2018, By Sector of Origin
Figure 49 Peru Export and Import Value & Volume, 2018-2019 ($)
Figure 50 Colombia Immunotoxins Market Value & Volume, 2019-2024 ($)
Figure 51 Colombia GDP and Population, 2018-2019 ($)
Figure 52 Colombia GDP – Composition of 2018, By Sector of Origin
Figure 53 Colombia Export and Import Value & Volume, 2018-2019 ($)
Figure 54 Costa Rica Immunotoxins MarketCosta Rica 3D Printing Market Value & Volume, 2019-2024 ($)
Figure 55 Costa Rica GDP and Population, 2018-2019 ($)
Figure 56 Costa Rica GDP – Composition of 2018, By Sector of Origin
Figure 57 Costa Rica Export and Import Value & Volume, 2018-2019 ($)
Figure 58 Europe Immunotoxins Market Value & Volume, 2019-2024 ($)
Figure 59 U.K Immunotoxins Market Value & Volume, 2019-2024 ($)
Figure 60 U.K GDP and Population, 2018-2019 ($)
Figure 61 U.K GDP – Composition of 2018, By Sector of Origin
Figure 62 U.K Export and Import Value & Volume, 2018-2019 ($)
Figure 63 Germany Immunotoxins Market Value & Volume, 2019-2024 ($)
Figure 64 Germany GDP and Population, 2018-2019 ($)
Figure 65 Germany GDP – Composition of 2018, By Sector of Origin
Figure 66 Germany Export and Import Value & Volume, 2018-2019 ($)
Figure 67 Italy Immunotoxins Market Value & Volume, 2019-2024 ($)
Figure 68 Italy GDP and Population, 2018-2019 ($)
Figure 69 Italy GDP – Composition of 2018, By Sector of Origin
Figure 70 Italy Export and Import Value & Volume, 2018-2019 ($)
Figure 71 France Immunotoxins Market Value & Volume, 2019-2024 ($)
Figure 72 France GDP and Population, 2018-2019 ($)
Figure 73 France GDP – Composition of 2018, By Sector of Origin
Figure 74 France Export and Import Value & Volume, 2018-2019 ($)
Figure 75 Netherlands Immunotoxins Market Value & Volume, 2019-2024 ($)
Figure 76 Netherlands GDP and Population, 2018-2019 ($)
Figure 77 Netherlands GDP – Composition of 2018, By Sector of Origin
Figure 78 Netherlands Export and Import Value & Volume, 2018-2019 ($)
Figure 79 Belgium Immunotoxins Market Value & Volume, 2019-2024 ($)
Figure 80 Belgium GDP and Population, 2018-2019 ($)
Figure 81 Belgium GDP – Composition of 2018, By Sector of Origin
Figure 82 Belgium Export and Import Value & Volume, 2018-2019 ($)
Figure 83 Spain Immunotoxins Market Value & Volume, 2019-2024 ($)
Figure 84 Spain GDP and Population, 2018-2019 ($)
Figure 85 Spain GDP – Composition of 2018, By Sector of Origin
Figure 86 Spain Export and Import Value & Volume, 2018-2019 ($)
Figure 87 Denmark Immunotoxins Market Value & Volume, 2019-2024 ($)
Figure 88 Denmark GDP and Population, 2018-2019 ($)
Figure 89 Denmark GDP – Composition of 2018, By Sector of Origin
Figure 90 Denmark Export and Import Value & Volume, 2018-2019 ($)
Figure 91 APAC Immunotoxins Market Value & Volume, 2019-2024 ($)
Figure 92 China Immunotoxins MarketValue & Volume, 2019-2024
Figure 93 China GDP and Population, 2018-2019 ($)
Figure 94 China GDP – Composition of 2018, By Sector of Origin
Figure 95 China Export and Import Value & Volume, 2018-2019 ($)Immunotoxins MarketChina Export and Import Value & Volume, 2018-2019 ($)
Figure 96 Australia Immunotoxins Market Value & Volume, 2019-2024 ($)
Figure 97 Australia GDP and Population, 2018-2019 ($)
Figure 98 Australia GDP – Composition of 2018, By Sector of Origin
Figure 99 Australia Export and Import Value & Volume, 2018-2019 ($)
Figure 100 South Korea Immunotoxins Market Value & Volume, 2019-2024 ($)
Figure 101 South Korea GDP and Population, 2018-2019 ($)
Figure 102 South Korea GDP – Composition of 2018, By Sector of Origin
Figure 103 South Korea Export and Import Value & Volume, 2018-2019 ($)
Figure 104 India Immunotoxins Market Value & Volume, 2019-2024 ($)
Figure 105 India GDP and Population, 2018-2019 ($)
Figure 106 India GDP – Composition of 2018, By Sector of Origin
Figure 107 India Export and Import Value & Volume, 2018-2019 ($)
Figure 108 Taiwan Immunotoxins MarketTaiwan 3D Printing Market Value & Volume, 2019-2024 ($)
Figure 109 Taiwan GDP and Population, 2018-2019 ($)
Figure 110 Taiwan GDP – Composition of 2018, By Sector of Origin
Figure 111 Taiwan Export and Import Value & Volume, 2018-2019 ($)
Figure 112 Malaysia Immunotoxins MarketMalaysia 3D Printing Market Value & Volume, 2019-2024 ($)
Figure 113 Malaysia GDP and Population, 2018-2019 ($)
Figure 114 Malaysia GDP – Composition of 2018, By Sector of Origin
Figure 115 Malaysia Export and Import Value & Volume, 2018-2019 ($)
Figure 116 Hong Kong Immunotoxins MarketHong Kong 3D Printing Market Value & Volume, 2019-2024 ($)
Figure 117 Hong Kong GDP and Population, 2018-2019 ($)
Figure 118 Hong Kong GDP – Composition of 2018, By Sector of Origin
Figure 119 Hong Kong Export and Import Value & Volume, 2018-2019 ($)
Figure 120 Middle East & Africa Immunotoxins MarketMiddle East & Africa 3D Printing Market Value & Volume, 2019-2024 ($)
Figure 121 Russia Immunotoxins MarketRussia 3D Printing Market Value & Volume, 2019-2024 ($)
Figure 122 Russia GDP and Population, 2018-2019 ($)
Figure 123 Russia GDP – Composition of 2018, By Sector of Origin
Figure 124 Russia Export and Import Value & Volume, 2018-2019 ($)
Figure 125 Israel Immunotoxins Market Value & Volume, 2019-2024 ($)
Figure 126 Israel GDP and Population, 2018-2019 ($)
Figure 127 Israel GDP – Composition of 2018, By Sector of Origin
Figure 128 Israel Export and Import Value & Volume, 2018-2019 ($)
Figure 129 Entropy Share, By Strategies, 2018-2019* (%)Immunotoxins Market
Figure 130 Developments, 2018-2019*Immunotoxins Market
Figure 131 Company 1 Immunotoxins Market Net Revenue, By Years, 2018-2019* ($)
Figure 132 Company 1 Immunotoxins Market Net Revenue Share, By Business segments, 2018 (%)
Figure 133 Company 1 Immunotoxins Market Net Sales Share, By Geography, 2018 (%)
Figure 134 Company 2 Immunotoxins Market Net Revenue, By Years, 2018-2019* ($)
Figure 135 Company 2 Immunotoxins Market Net Revenue Share, By Business segments, 2018 (%)
Figure 136 Company 2 Immunotoxins Market Net Sales Share, By Geography, 2018 (%)
Figure 137 Company 3Immunotoxins Market Net Revenue, By Years, 2018-2019* ($)
Figure 138 Company 3Immunotoxins Market Net Revenue Share, By Business segments, 2018 (%)
Figure 139 Company 3Immunotoxins Market Net Sales Share, By Geography, 2018 (%)
Figure 140 Company 4 Immunotoxins Market Net Revenue, By Years, 2018-2019* ($)
Figure 141 Company 4 Immunotoxins Market Net Revenue Share, By Business segments, 2018 (%)
Figure 142 Company 4 Immunotoxins Market Net Sales Share, By Geography, 2018 (%)
Figure 143 Company 5 Immunotoxins Market Net Revenue, By Years, 2018-2019* ($)
Figure 144 Company 5 Immunotoxins Market Net Revenue Share, By Business segments, 2018 (%)
Figure 145 Company 5 Immunotoxins Market Net Sales Share, By Geography, 2018 (%)
Figure 146 Company 6 Immunotoxins Market Net Revenue, By Years, 2018-2019* ($)
Figure 147 Company 6 Immunotoxins Market Net Revenue Share, By Business segments, 2018 (%)
Figure 148 Company 6 Immunotoxins Market Net Sales Share, By Geography, 2018 (%)
Figure 149 Company 7 Immunotoxins Market Net Revenue, By Years, 2018-2019* ($)
Figure 150 Company 7 Immunotoxins Market Net Revenue Share, By Business segments, 2018 (%)
Figure 151 Company 7 Immunotoxins Market Net Sales Share, By Geography, 2018 (%)
Figure 152 Company 8 Immunotoxins Market Net Revenue, By Years, 2018-2019* ($)
Figure 153 Company 8 Immunotoxins Market Net Revenue Share, By Business segments, 2018 (%)
Figure 154 Company 8 Immunotoxins Market Net Sales Share, By Geography, 2018 (%)
Figure 155 Company 9 Immunotoxins Market Net Revenue, By Years, 2018-2019* ($)
Figure 156 Company 9 Immunotoxins Market Net Revenue Share, By Business segments, 2018 (%)
Figure 157 Company 9 Immunotoxins Market Net Sales Share, By Geography, 2018 (%)
Figure 158 Company 10 Immunotoxins Market Net Revenue, By Years, 2018-2019* ($)
Figure 159 Company 10 Immunotoxins Market Net Revenue Share, By Business segments, 2018 (%)
Figure 160 Company 10 Immunotoxins Market Net Sales Share, By Geography, 2018 (%)
Figure 161 Company 11 Immunotoxins Market Net Revenue, By Years, 2018-2019* ($)
Figure 162 Company 11 Immunotoxins Market Net Revenue Share, By Business segments, 2018 (%)
Figure 163 Company 11 Immunotoxins Market Net Sales Share, By Geography, 2018 (%)
Figure 164 Company 12 Immunotoxins Market Net Revenue, By Years, 2018-2019* ($)
Figure 165 Company 12 Immunotoxins Market Net Revenue Share, By Business segments, 2018 (%)
Figure 166 Company 12 Immunotoxins Market Net Sales Share, By Geography, 2018 (%)
Figure 167 Company 13Immunotoxins Market Net Revenue, By Years, 2018-2019* ($)
Figure 168 Company 13Immunotoxins Market Net Revenue Share, By Business segments, 2018 (%)
Figure 169 Company 13Immunotoxins Market Net Sales Share, By Geography, 2018 (%)
Figure 170 Company 14 Immunotoxins Market Net Revenue, By Years, 2018-2019* ($)
Figure 171 Company 14 Immunotoxins Market Net Revenue Share, By Business segments, 2018 (%)
Figure 172 Company 14 Immunotoxins Market Net Sales Share, By Geography, 2018 (%)
Figure 173 Company 15 Immunotoxins Market Net Revenue, By Years, 2018-2019* ($)
Figure 174 Company 15 Immunotoxins Market Net Revenue Share, By Business segments, 2018 (%)
Figure 175 Company 15 Immunotoxins Market Net Sales Share, By Geography, 2018 (%)